Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, accounting for \>740,000 new cases and 690,000 mortalities per year ([@b1-ol-08-03-1249]). Half of these new cases and mortalities were estimated to occur in China. The high rates of HCC in China are largely due to the prevalence of chronic hepatitis B virus (HBV) infection ([@b2-ol-08-03-1249]). The RAS/RAF and PI3K/PTEN signaling pathways play central roles in hepatocarcinogenesis ([@b3-ol-08-03-1249]). The aberrant activation of the RAS/RAF and PI3K/PTEN signaling pathways is associated with poor prognosis in cancer patients ([@b4-ol-08-03-1249],[@b5-ol-08-03-1249]). HBV also utilizes the pathways for the control of hepatocyte survival and viral replication ([@b6-ol-08-03-1249],[@b7-ol-08-03-1249]). Mutations of key components (such as *RAS*, *RAF*, *PIK3CA*, *PIK3R1* and *PTEN*) in the RAS/RAF and PI3K/PTEN pathways lead to the dysregulation of the two cascades ([@b8-ol-08-03-1249]). The *RAS* family comprises three members: *KRAS*, *NRAS* and *HRAS*. Somatic mutations in the *RAS* family are common in numerous human cancer types, including pancreatic, thyroid, colorectal, liver, kidney and lung ([@b9-ol-08-03-1249]). *BRAF* is the most frequently mutated gene in the *RAF* family, and the *BRAF* mutation has been reported in 61% of melanoma, 53% of papillary thyroid cancer and 11.5% of colorectal cancer patients ([@b10-ol-08-03-1249]--[@b12-ol-08-03-1249]). The PI3K gene comprises *PIK3CA,* which encodes the catalytically active p110α subunit, and *PIK3R1,* encoding the p85α regulatory subunit ([@b13-ol-08-03-1249]). *PIK3CA* is mutated in numerous tumor types, with the frequency ranging from 4 to 32% in breast, colorectal, endometrial, brain, gastric and lung cancer ([@b14-ol-08-03-1249]--[@b17-ol-08-03-1249]). *PIK3R1* mutations were identified in 43% of endometrial cancer, 4% of ovarian cancer and 2% of colon cancer ([@b18-ol-08-03-1249]--[@b19-ol-08-03-1249]). PTEN acts as a negative regulator of the PI3K pathway and *PTEN* mutations lead to a reduction of its phosphatase activity ([@b20-ol-08-03-1249]). Mutations of the *PTEN* gene are associated with a wide variety of human tumors ([@b21-ol-08-03-1249]).

Inhibitors targeting the RAS/RAF and PI3K/PTEN pathways have been developed and the clinical responses of patients were observed to differ according to the genetic alterations of the critical components of the two cascades ([@b22-ol-08-03-1249]). However, few data are available regarding the prevalence of *KRAS*, *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* mutations in Chinese patients with HCC. In the present study, we conducted mutational analysis of 57 somatic hotspot mutations in *KRAS*, *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* in 36 Chinese patients with HCC.

Materials and methods
=====================

Patients and tissue samples
---------------------------

Thirty-six patients with HCC undergoing surgery at Nantong Tumor Hospital (Nantong, China) between 2009 and 2011 were enrolled in this study. Tumor samples and adjacent normal liver tissues from the corresponding patients were fixed with 10% formalin, embedded in paraffin and stained with hematoxylin and eosin (H&E). Tumor staging was performed according to the Barcelona Clinic Liver Cancer (BCLC) staging classification ([@b23-ol-08-03-1249]). This study was approved by the Ethics Committee of Nantong Tumor Hospital. Written informed consent was obtained from each patient prior to sample collection.

Genomic DNA extraction
----------------------

Tumor areas and non-tumorous tissue areas were identified on H&E-stained slides. Genomic DNA was extracted from formalin-fixed paraffin-embedded tissues of HCC with the QIAamp DNA FFPE Tissue kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. Briefly, samples were placed into Eppendorf tubes and the paraffin was removed. Next, the tubes were incubated with proteinase K (Qiagen GmbH) at 56°C for 1 h. Following proteinase K digestion, the samples were incubated at 90°C for 1 h and DNA was extracted using QIAamp MinElute columns (Qiagen GmbH).

Mutation analysis
-----------------

Polymerase chain reaction (PCR) was performed to amplify the gene fragments including the hotspot mutations shown in [Table I](#tI-ol-08-03-1249){ref-type="table"}. The selection of the hotspots was based on the prevalence of mutations in cancers identified in the COSMIC database ([@b24-ol-08-03-1249]). A 50 μl volume of PCR was prepared using the Taq PCR Master Mix kit (Qiagen GmbH), according to the manufacturer's instructions. The thermocycling was performed at 94°C for 3 min; 35 cycles of 94°C for 30 sec, 56°C for 30 sec and 72°C for 60 sec; followed by a final 10 min at 72°C. PCR products were run on 1.5% agarose gel electrophoresis and visualized with ultraviolet light to confirm sizes. DNA purification was performed with the QIAprep Gel Extraction kit (Qiagen GmbH) according to the manufacturer's instructions. Briefly, the DNA fragments were excised from the agarose gel with a scalpel and placed in a colorless tube. DNA cleanup was conducted using QIAquick spin columns (Qiagen GmbH). Direct DNA sequencing was performed using a Big Dye Terminator (v3.1) kit (Applied Biosystems, Foster City, CA, USA). The sequencing products were run on an Applied Biosystems 3130XL Genetic Analyzer (Applied Biosystems). DNA sequencing results were analyzed using Chromas software (Technelysium, Brisbane, Queensland, Australia). The primers used for the PCR are listed in [Table I](#tI-ol-08-03-1249){ref-type="table"}.

Results
=======

Clinicopathological characteristics
-----------------------------------

Of 36 patients with HCC, the median age was 54 years (range, 40--77 years), including 33 males and three females. The majority of the cases had HCC associated with HBV infection (34/36; 94.4%). All patients were negative in hepatitis C virus infection. The concentrations of serum AFP of 16 patients (16/36; 44.4%) were higher than 400 ng/ml. The BCLC staging classification was used to classify the cancer staging ([@b23-ol-08-03-1249]). There were 2, 25, 8, 1 and 0 cases of stages 0 to D, respectively ([Table II](#tII-ol-08-03-1249){ref-type="table"}).

Mutation analysis of key genes in the RAS/RAF and PI3K/PTEN pathways
--------------------------------------------------------------------

We analyzed hotspot-containing gene fragments of key genes in RAS/RAF and PI3K/PTEN pathways using PCR amplification followed by direct sequencing. The hotspots were listed in [Table I](#tI-ol-08-03-1249){ref-type="table"}. In all, two samples (Sample \#13 and \#35) had point mutations in codon 61 (Q61H) of the *KRAS* gene and the mutation rate was 5.6% ([Fig. 1](#f1-ol-08-03-1249){ref-type="fig"}). In the two cases, codon 61 was altered from CAA, coding for Gln, to CAC, coding for His. To confirm the two mutations occurred at the somatic level, we tested codon 61 mutation status in non-tumorous tissues from the two patients. The results showed that codon 61 was wild-type in normal tissues from Sample \#13 and \#35 ([Fig. 1](#f1-ol-08-03-1249){ref-type="fig"}). The two patients harboring *KRAS* mutation were male. Patient no. 13 was 49 years old, had HBV infection and stage A HCC, and an AFP level of 3.4 ng/ml. Patient no. 35 was 69 years old, had stage B HCC and was negative for HBV infection, with an AFP level of 1.95 ng/ml. No other mutations in the *HRAS*, *NRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* genes were identified.

Discussion
==========

Targeting the RAS/RAF and PI3K/PTEN pathways are novel therapeutic strategies that may be exploited for the treatment of HCC ([@b8-ol-08-03-1249]). As the RAF-kinase inhibitor sorafenib has been demonstrated to be effective in the treatment of HCC, *BRAF* mutations have become a favored target in HCC treatment recently ([@b25-ol-08-03-1249]). However, the somatic mutation prevalence and distribution of the key genes in the two pathways remain largely unknown in Chinese patients with HCC. Therefore, the present study set out to examine the frequency of hotspot mutations of the *KRAS*, *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* genes in 36 human HCC tissues from Chinese patients. Only *KRAS* somatic mutations were identified, with a mutation rate of 5.6%.

The incidence of *KRAS* mutations has been found in 80% of advanced pancreatic cancer ([@b26-ol-08-03-1249]), 45% of cholangiocarcinoma ([@b27-ol-08-03-1249]) and 32% of colorectal cancer ([@b28-ol-08-03-1249]) patients. COSMIC database has shown that mutations in codons 12, 13 and 61 of the *KRAS* gene are known hotspots in various types of cancer. The frequency and distribution of *KRAS* mutation in HCC from several previous studies are summarized in [Table III](#tIII-ol-08-03-1249){ref-type="table"}. The majority of these studies have shown that *KRAS* gene mutations occur infrequently (\<10%) in HCC. The codon 12 accounts for the majority of *KRAS* mutations detected (\~70%), whereas mutations affecting codon 13 and codon 61 account for the remaining 30%. One third of the twelve studies did not evaluate the *KRAS* codon 61 mutation status, which may cause bias in the distribution of the *KRAS* mutation. Three whole exome sequencing studies conducted mutational screening in all *KRAS* exons and found that the mutations were clustered in the hotspots ([@b29-ol-08-03-1249]--[@b31-ol-08-03-1249]). In the current study, mutations were detected in codons 12, 13 and 61 of the *KRAS* gene, and two out of 36 (5.6%) HCCs harbored *KRAS* mutations in codon 61. Therefore, *KRAS* gene mutations may participate in hepatocellular carcinogenesis.

The present study also investigated the hotspot mutations in *NRAS* and *HRAS*, but found no mutation in the two genes. Few studies have focused on the mutation incidence of these two *RAS* family members in Chinese patients with HCC. A whole exome sequencing study identified no mutation in these two genes in a Chinese population ([@b31-ol-08-03-1249]). Challen *et al* found that the frequency of *NRAS* mutations was 15.8%, but did not identify *HRAS* mutations, in British patients with HCC ([@b32-ol-08-03-1249]). Taketomi *et al* reported neither *NRAS* nor *HRAS* mutations were detected in Japanese HCC cases ([@b33-ol-08-03-1249]). Thus, the mutational activation of *NRAS* and *HRAS* genes is an uncommon event in the pathogenesis of HCCs.

*BRAF* mutations can abnormally activate downstream signaling pathways in HCC and act as indicator of cetuximab resistance in patients with colon cancer ([@b34-ol-08-03-1249],[@b35-ol-08-03-1249]). *BRAF* mutations are believed to be rare in HCCs. Previously, no *BRAF* mutations were identified in German and Chinese populations ([@b27-ol-08-03-1249],[@b36-ol-08-03-1249]). However, Colombino *et al* detected that the *BRAF* gene was highly mutated in \~23% of Italian HCC cases ([@b37-ol-08-03-1249]). In the current series, no *BRAF* mutations were observed, indicating that *BRAF* mutation does not play a major role in abnormal activation of RAS/RAF signaling pathway.

*PIK3CA*, *PIK3R1* and *PTEN* are key genes in the PI3K/PTEN pathway ([@b8-ol-08-03-1249]). In the current study, it was found that mutations were absent in the three genes. Previously, *PIK3CA* was observed to be frequently mutated in Korean and Italian patients with HCC, with mutation rates of 35.6 and 28%, respectively ([@b15-ol-08-03-1249],[@b37-ol-08-03-1249]). However, Tanaka *et al* did not identify *PIK3CA* mutations in Japanese patients with HCC, and Riener *et al* reported that the *PIK3CA* mutation incidence was 2% in Swiss patients with HCC ([@b38-ol-08-03-1249],[@b39-ol-08-03-1249]). In two studies in Chinese patients with HCC, the mutation rates were 1.6 and 1.1% ([@b36-ol-08-03-1249],[@b40-ol-08-03-1249]), which were similar to those of the present study. The conflicting data may be due to the different genetic backgrounds of the populations, HBV infection status and smaller sample size in the current study. *PIK3R1* mutation has been found to occur infrequently in numerous cancer types, including ovarian and colon cancer ([@b19-ol-08-03-1249]), and the present study showed a low frequency of alteration of *PIK3R1* in HCC. Inactivation of *PTEN* in HCC may be largely due to frequent loss of heterozygosity of the *PTEN* allele; the frequency was identified to be ≤44.4% ([@b41-ol-08-03-1249]). Wang *et al* investigated *PTEN* mutations in exons 5 and 8, but failed to detect any ([@b42-ol-08-03-1249]), which was in agreement with the results of the present study. Mutations in the *PIK3CA*, *PIK3R1* and *PTEN* genes rarely occur in HCC, suggesting that somatic point mutations of these three genes may not play an important role in HCC in the Chinese population. However, further research is necessary to confirm these results in larger sample size.

In summary, the present study investigated the prevalence of *KRAS*, *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* mutations in 57 hotspot mutations. Two cases of *KRAS* mutation were identified among 36 HCC cases. The findings indicated that point mutations in the *KRAS* gene, but not mutations in the *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* genes, at the somatic level contribute to the abnormal activation of the RAS/RAF and PI3K/PTEN pathways in HCC. Considering the low frequency of key genes in the RAS/RAF and PI3K/PTEN signaling pathways, other mechanisms to activate the RAS/RAF and PI3K/PTEN pathways, such as gene amplification, deletion, and aberrant methylation, may be involved in the development and progression of HCC.
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###### 

Primers used for polymerase chain reaction in this study.

  Gene     Mutation                                         Forward primer sequence (5′ to 3′)   Reverse primer sequence (5′ to 3′)
  -------- ------------------------------------------------ ------------------------------------ ------------------------------------
  KRAS     G12C, G12D, G13S, G13D, L19F, Q22K               CTTAAGCGTCGATGGAGGAG                 CCCTGACATACTCCCAAGGA
           A59T, Q61E, Q61R, Q61H                           GGTGCTTAGTGGCCATTTGT                 CCTAGGTTTCAATCCCAGCA
           A146T                                            TTGTGGACAGGTTTTGAAAGA                AGAAACCAAAGCCAAAAGCA
  NRAS     G12S, G12V, G13R, G13V, A18T                     GCCCAAGGACTGTTGAAAAA                 CCGACAAGTGAGAGACAGGA
           Q61K, Q61R, Q61H                                 GGCAGAAATGGGCTTGAATA                 AGGTTAATATCCGCAAATGAC
  HRAS     G12S, G12V, G13R, G13D                           GTGGGTTTGCCCTTCAGAT                  TGGTGGATGTCCTCAAAAGA
           Q61K, Q61R, Q61H                                 TGGCTGTGTGAACTCCCC                   GTCAGTGAGTGCTGCTCCC
  BRAF     G464V, G466V, G469A, V471F                       CACTTGGTAGACGGGACTCG                 AGTTTATTGATGCGAACAGTGA
           D594G, L597V, V600E                              AACTCTTCATAATGCTTGCTCTGA             AGCCTCAATTCTTACCATCCA
  PIK3CA   R38G, Q75E, R108H                                GCCTAATCAAGTCAAACTATGGAA             AAGCTTTATGGTTATTTGCATTTT
           G118D                                            ATGTTTGCTGCCTTTGCTCT                 ATAAGCAGTCCCTGCCTTCA
           C378R                                            TAAGGGGATTGTGGGCCTAT                 AATGGGGTCTTGCTTTGTTG
           C420R                                            CTCATGCTTGCTTTGGTTCA                 TTGGCATGCTCTTCAATCAC
           P539R, E542K, E545K, E545G, Q546K                GATTGGTTCTTTCCTGTCTCTG               CCACAAATATCAATTTACAACCATTG
           T1025A, M1043T, M1043I, H1047Y, H1047R, H1047L   CATTTGCTCCAAACTGACCA                 CACCCCAAGCATTTTTCTTC
  PIK3R1   G376R                                            CAGACGGGACCTTTTTGGTA                 AACAAAATAGCTGACATGGAAACA
           K459E, D464H                                     GGCTTCTCTGACCCATTAACC                CCCCACCTCATTCGTAAAAA
           L570P                                            GGAAGAGAAGCCACGCTTTA                 CCCAACCACTCGTTCAACTT
  PTEN     R130G, R130Q                                     CCGTATAGCGTAAATTCCCAGA               TCTCAGATCCAGGAAGAGGAA
  R233X    TGCTTGAGATCAAGATTGCAG                            GCCATAAGGCCTTTTCCTTC                 

###### 

Clinical characteristics of hepatocellular carcinoma patients.

  Characteristic    Value
  ----------------- -------------
  Age, years        
   Median (range)   54 (40--77)
  Gender, n (%)     
   Male             33 (91.7)
   Female           3 (8.3)
  Etiology, n (%)   
   HBV(+)           34 (94.4)
   HBV(−)           2 (5.6)
  AFP, n (%)        
   \>400 ng/ml      16 (44.4)
   ≤400 ng/ml       20 (55.6)
  Stage, n (%)      
   0                2 (5.6)
   A                25 (69.4)
   B                8 (22.2)
   C                1 (2.8)
   D                0 (0.0)

###### 

Reported point mutations in codons 12, 13, and 61 of *KRAS* in hepatocellular carcinomas.

  Author (ref)                               Population   No. of patients   Codon 12   Codon 13   Codon 61   Frequency (%)
  ------------------------------------------ ------------ ----------------- ---------- ---------- ---------- ---------------
  Zuo *et al* ([@b36-ol-08-03-1249])         Chinese      64                2          1          NA         4.7
  Huang *et al* ([@b31-ol-08-03-1249])       Chinese      10                0          0          0          0.0
  Taketomi *et al* ([@b33-ol-08-03-1249])    Japanese     61                0          1          0          1.6
  Tsuda *et al* ([@b43-ol-08-03-1249])       Japanese     30                1          0          0          3.3
  Taniguchi *et al* ([@b44-ol-08-03-1249])   Japanese     15                0          0          NA         0.0
  Fujimoto *et al* ([@b29-ol-08-03-1249])    Japanese     27                0          0          0          0.0
  Tada *et al* ([@b45-ol-08-03-1249])        Japanese     12                0          0          0          0.0
  Bose *et al* ([@b46-ol-08-03-1249])        Indian       30                2          0          0          6.7
  Tannapfel *et al* ([@b27-ol-08-03-1249])   German       25                0          0          NA         0.0
  Weihrauch *et al* ([@b47-ol-08-03-1249])   German       20                3          0          NA         15.0
  Challen *et al* ([@b32-ol-08-03-1249])     British      19                0          NA         1          5.3
  Guichard *et al* ([@b30-ol-08-03-1249])    French       149               1          0          1          1.3
  Colombino *et al* ([@b37-ol-08-03-1249])   Italian      65                1          0          0          1.5

NA, not available.

[^1]: Contributed equally
